# US 2012/0251587 A1 · Diabetes treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251587 A1
- Document ID: US20120251587A1
- Status: Published application
- Kind: A1
- Application number: 13/391,269
- Filed: 2010-08-17
- Published: 2012-10-04
- Earliest claimed: 2009-08-17
- Assignees: Academisch Ziekenhuis Leiden (H.O.D.N. Lumc); Universiteit Twente
- Inventors: Aart Alexander Van Apeldoorn; Hermanus Bernardus Johannes Karperien; Clemens Antoni Van Blitterswijk; Eelco Johan Paul De Koning; Marten Alexander Engelse
- Web page: https://patentgrep.com/patent/US20120251587A1

## CPC

- C12N 5/0677: {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}
- A61K 35/39: Pancreas; Islets of Langerhans (Langerhans cells of epidermis A61K35/36)
- A61L 27/18: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- A61L 27/3804: {characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells}
- A61L 27/3839: {characterised by the site of application in the body (materials for artificial blood vessels A61L27/507; materials for use in artificial skin A61L27/60)}
- A61L 27/56: Porous materials, {e.g. foams or sponges}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C12N 5/0068: {General culture methods using substrates (for specific animal cell type C12N5/06)}
- C12N 2533/30: Synthetic polymers
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention is directed to a treatment of diabetes, a scaffold and a method of preparing a scaffold. In a first aspect, this object is met by providing a scaffold comprising beta cell aggregates, wherein the aggregates are distributed over the scaffold in a predetermined pattern.

## Claims

### Claim 1

Scaffold comprising beta cell aggregates, wherein the aggregates are distributed over the scaffold in a predetermined pattern.

### Claim 2 (depends on 1)

Scaffold according to claim 1, wherein the beta cell aggregates are distributed in such a pattern that they are homogeneously distributed over the scaffold.

### Claim 3 (depends on 1)

Scaffold according to claim 1 wherein the beta cell aggregates are islets of Langerhans isolated from a donor pancreas.

### Claim 4 (depends on 1)

Scaffold according to claim 1, wherein the scaffold comprises a scaffold sheet comprising a first layer, which first layer is a polymer layer.

### Claim 5 (depends on 4)

Scaffold according to claim 4, wherein the first layer is a porous layer.

### Claim 6 (depends on 5)

Scaffold according to claim 5, wherein the first layer comprises a surface comprising microwells, wherein each microwell has a diameter of 20-800 μm.

### Claim 7 (depends on 4)

Scaffold according to claim 4, wherein the scaffold sheet further comprises a second layer, which second layer is a hydrogel layer.

### Claim 8 (depends on 7)

Scaffold according to claim 7, wherein the hydrogel layer is a fibrin or platelet derived gel layer.

### Claim 9 (depends on 1)

Scaffold according to claim 1, wherein each aggregate has a diameter of less than 180 μm, as measured with a scanning electron microscope.

### Claim 10 (depends on 1)

Scaffold according to claim 1, wherein each cell aggregate comprises 20-500 cells.

### Claim 11 (depends on 4)

Scaffold according to claim 4, wherein the polymer layer is a layer having substantially no adherence with the beta cell aggregates.

### Claim 12 (depends on 6)

Scaffold according to claim 6, wherein the scaffold sheet further comprises a second layer, which second layer is a hydrogel layer, and wherein the hydrogel layer seals the microwells, thus encapsulating the agglomerates in the scaffold.

### Claim 13 (depends on 7)

Scaffold according to claim 7, wherein the hydrogel layer is made of a material selected from the group consisting of poly(2-hydroxyethyl methacrylate); alginates; agarose; collagen derived hydrogels; platelet derived hydrogels; pluronic acid derived hydrogels; hydrogels of dextran, hyaluronic acid, chitosan, or heparin; and a combination thereof.

### Claim 14 (depends on 4)

Scaffold according to claim 4, wherein the first layer is made of a material selected from the group consisting of polylactic acid (PLA), polypropylene (PP), polycarbonate (PC), cyclic olefin polymer (COP), poly(trimethylene carbonate), caprolactone, poly(lactic-co-glycolic acid) (PLGA), polyurethane (PU), PU derived biomaterials and a copolymer of a polyalkylene glycol terephtalate and an aromatic polyester.

### Claim 15 (depends on 1)

Scaffold according to claim 1, further comprising growth factors and/or factors that stimulate survival of the beta cells.

### Claim 16 (depends on 1)

A method to treat diabetes which comprises applying the scaffold according to claim 1 to a subject in need of such treatment.

### Claim 17 (depends on 3)

Method for preparing a scaffold according to claim 3, comprising the steps of:
isolating islets of Langerhans from a pancreas; and
providing a polymer layer comprising microwells; and
seeding the microwells with beta cell agglomerates originating from the isolated islet of Langerhans; and
covering the microwells with a hydrogel layer.

### Claim 18 (depends on 17)

Method according to claim 17, wherein the islets of Langerhans are directly seeded in the microwells.

### Claim 19 (depends on 17)

Method according to claim 17, wherein the microwells have an average diameter of 100-350 μm.

### Claim 20 (depends on 17)

Method according to claim 17, further comprising the step of size fractionation of the obtained islet of Langerhans cells, prior to seeding.

### Claim 21 (depends on 15)

Scaffold according to claim 15 wherein the scaffold sheet further comprises a first layer and a second layer, which second layer is a hydrogel layer, and said factors are incorporated in the second layer.
